Poolbeg Pharma's NED and Scientific Advisory Board member, Professor Luke O'Neill sheds light on POLB 001's in the oncology space. POLB 001 has the potential to be an effective oral preventative therapy to address the significant unmet medical need in cancer immunotherapy-induced Cytokine Release Syndrome (CRS). #Cancer #CRS #CART #ScientificResearch #POLB #Oncology
Poolbeg Pharma plc
Biotechnology Research
Focused on the development & commercialisation of innovative medicines. Ticker: POLB
About us
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues. Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
- Website
-
https://www.poolbegpharma.com/
External link for Poolbeg Pharma plc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Locations
-
Primary
Get directions
40 Bank Street, Floor 24
London, E14 5NR, GB
-
Get directions
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin 2, D02 T292, IE
Employees at Poolbeg Pharma plc
-
Eddie Gibson
Associate at Wickenstones Ltd
-
Jeremy Skillington, PhD
Chief Executive Officer at Poolbeg Pharma
-
Brendan Buckley
Chief Medical Officer at Teckro
-
Cathal Friel
Dublin, London & Vienna, Chairman and Co-Founder at Open Orphan Plc (now hVIVO plc) & Poolbeg Pharma Plc, Co-Founder & Director at Euro Green…
Updates
-
The Korean Intellectual Property Office has notified its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application providing protection to December 2038. 👉 Claims cover POLB 001 for the treatment of severe influenza ✅ POLB 001 has strong potential across multiple disease areas 🤝 Further strengthening our global IP portfolio & enhancing the value & attractiveness of POLB 001 for prospective partners Learn more: https://lnkd.in/eRSw_fYj #POLB #Patent #IntellectualProperty #PatentProtection
-
Our Chief Executive Officer Jeremy Skillington, PhD will be presenting Poolbeg Pharma, our exciting drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS at OBN (UK) Ltd's Bio Trinity in London. 📅 Wednesday 2 April 👉 Session: Science Spotlight 8 - Rare Disease Meet Jeremy there to learn more about our high value programmes. Learn more: https://lnkd.in/eHZCGhZM #POLB #BioTrinity #London
-
-
We will be attending Master Investor on Saturday 29 March in London. Meet with the team to learn more about Poolbeg Pharma 🤝 Highly experienced team 👉 High value programmes 🔬 Diversified pipeline 💊 Focus on partnering Get your tickets here: https://lnkd.in/ezGVkCDE #POLB #MasterInvestor25 #Investor #AIM
-
-
Learn more about the planned POLB 001 Phase 2a clinical trial from our Poolbeg Pharma plc CEO Jeremy Skillington, PhD 📅 Anticipated to start later this year 🔍 Top-line data expected in 2026 👉 Key objectives/endpoints If you missed our Investor Meet Company presentation, catch up on the replay available below: https://lnkd.in/epSPVrpr #POLB #AIM #InvestorMeet #Oncology #Phase2 #ScientificResearch #Immunotherapies
-
At our recent Investor Meet Company presentation we highlighted POLB 001's rapid progress in drug development, from concept to validated preclinical data in just 12 months and Phase 2 ready in just 24 months. Here, our CEO Jeremy Skillington, PhD provides an overview of POLB 001's strategic expansion to address the critical unmet need in cancer immunotherapy-induced CRS. 💰 <$10bn Market opportunity identified ✅ Independent KOL's endorsement 🔬 Preclinical data generated & presented ☑️ LPS data generated & presented 🎯 Phase 2 ready 👉 Patent applications filed #POLB #CRS #Immunotherapy #Phase2 #preclinical #scientificResearch #Oncology
-
We presented POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting in December. Learn more about the most significant results of this study from our Principal Scientist Liam Tremble Learn more about POLB 001 here: https://lnkd.in/eGgQBKFA #POLB #PreClinical #StudyData #CRS #Inflammation #Cancer #Immunotherapy #ASH24
-
If you missed yesterdays Investor Meet Company presentation, featuring our CEO Jeremy Skillington, PhD & Chairman Cathal Friel then you can now catch up on the full recording available here: https://lnkd.in/epSPVrpr #POLB #InvestorMeetCompany #CompanyPresentation #AIM
POOLBEG PHARMA PLC - Investor Presentation
https://www.youtube.com/
-
Our Executive Chairman, Cathal Friel, and Chief Executive Officer, Jeremy Skillington will provide a live presentation via the Investor Meet Company platform tomorrow 26 February 2025 at 5pm GMT. Register to attend here: https://lnkd.in/e-H_iSsf #POLB
-
-
Our Principal Scientist Liam Tremble gives an overview of Adalimumab & highlights why Poolbeg Pharma plc compared POLB 001 to this TNF antibody in our preclinical study which was presented at American Society of Hematology ASH 2024. #POLB #PreClinical #StudyData #CRS #Inflammation #Cancer #Immunotherapy #ASH24